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Metabolic Syndrome and Risk
of Acute Myocardial Infarction
A Case-Control Study of 26,903 Subjects From 52 Countries
Andrew Mente, PHD,*† Salim Yusuf, MBBS, DPHIL,*† Shofiqul Islam, MS,*
Matthew J. McQueen, MBCHB, PHD,*‡ Supachai Tanomsup, MD,§ Churchill L. Onen, MD,
Sumathy Rangarajan, MS,* Hertzel C. Gerstein, MD, MS,*† Sonia S. Anand, MD, PHD,*†
for the INTERHEART Investigators
Hamilton, Ontario, Canada; Bangkok, Thailand; and Gaborone, Botswana
Objectives This study examines the risk of acute myocardial infarction (MI) conferred by the metabolic syndrome (MS) and
its individual factors in multiple ethnic populations.
Background The risk of the MS on MI has not been well characterized, especially in multiple ethnic groups.
Methods Participants in the INTERHEART study (n  26,903) involving 52 countries were classified using the World
Health Organization (WHO) and International Diabetes Federation (IDF) criteria for MS, and their odds ratios
(ORs) for MI were compared with the individual MS component factors.
Results The MS is associated with an increased risk of MI, both using the WHO (OR: 2.69; 95% confidence interval [CI]:
2.45 to 2.95) and IDF (OR: 2.20; 95% CI: 2.03 to 2.38) definitions, with corresponding population attributable
risks of 14.5% (95% CI: 12.7% to 16.3%) and 16.8% (95% CI: 14.8% to 18.8%), respectively. The associations
are directionally similar across all regions and ethnic groups. Using the WHO definition, the association with MI
by the MS is similar to that of diabetes mellitus (OR: 2.72; 95% CI: 2.53 to 2.92) and hypertension (OR: 2.60;
95% CI: 2.46 to 2.76), and significantly stronger than that of the other component risk factors. The clustering of
3 risk factors with subthreshold values is associated with an increased risk of MI (OR: 1.50; 95% CI: 1.24 to
1.81) compared with having component factors with “normal” values. The IDF definition showed similar results.
Conclusions In this large-scale, multi-ethnic, international investigation, the risk of MS on MI is generally comparable to that
conferred by some, but not all, of its component risk factors. The characterization of risk factors, especially con-
tinuous variables, as dichotomous will underestimate risk and decrease the magnitude of association between
MS and MI. (J Am Coll Cardiol 2010;55:2390–8) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.053h
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Ehe common clustering of metabolic abnormalities includ-
ng abdominal obesity, elevated glucose, abnormal lipids,
nd elevated blood pressure has been extensively referred to
n the medical literature as the “metabolic syndrome” (MS)
1,2). The presence of MS is associated with an increased
isk of coronary heart disease (3–5), with limited evidence
hat this risk is greater than that conferred by its constituent
omponents (6). The value of classifying subjects with MS
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straZeneca, Novartis, Hoechst Marion Roussel [now Aventis], Knoll Pharmaceuticals 1as recently been called into question as the definition of
S is arbitrary (7,8), and the American Diabetes Associa-
ion and the European Association for the Study of Diabe-
es have called for an aggressive research agenda to bring
larity to this debate (8). In this large-scale, multi-ethnic,
nternational investigation, the objectives are to: 1) deter-
ine the risk of acute myocardial infarction (MI) among
atients with MS defined using existing criteria; 2) assess if
now Abbott], Bristol-Myers Squibb, and Sanofi-Synthélabo), and various national
odies in different countries. Dr. Mente is supported by a Heart and Stroke Foundation
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May 25, 2010:2390–8 Metabolic Syndrome and MI Riskhe risk of MS on MI is greater than the risk conferred by
he sum of individual component risk factors; 3) examine the
mpact on MI risk as more component risk factors are present,
nd the joint effects of these risk factors present in different
ombinations; 4) evaluate the risk conferred by risk factors
ith values below the threshold and the aggregation of
ubthreshold risk factors; and 5) examine whether the
ssociation of MS to MI varies across age, sex, and ethnic
ubgroups.
ethods
articipants. The INTERHEART study is a standardized
ase-control study of incident acute MI in 52 countries.
tudy participants consisted of 12,297 cases and 14,606
ontrols recruited from 262 centers in Asia, Europe, the
iddle East, Africa, Australia, North America, and South
merica. Incident cases of acute MI presenting within 24 h of
ymptom onset were eligible. At least 1 age-matched (as much
s 5 years older or younger) and sex-matched control was
ecruited per case. Criteria for selection of study subjects have
een described in detail previously (Online Appendix 1) (9).
rocedures. Structured questionnaires were administered,
nd physical examinations and blood samples were under-
aken in the same manner in cases and controls. All data
ere transferred to the Population Health Research Insti-
ute, McMaster University and Hamilton Health Sciences,
anada, where quality-control checks and statistical analy-
es were conducted. Information about risk factors includ-
ng hypertension and diabetes mellitus, physical measure-
ents including waist and hip circumference, blood
ressure, and body weight, and laboratory assessment of
polipoprotein (Apo) B and ApoA1 and hemoglobin (Hb)
1C was obtained using a standardized protocol and
aboratory measurement. Waist and hip circumferences
ere measured with a nonstretchable standard tape mea-
ure. Waist measurements were obtained over the unclothed
bdomen at the narrowest point between the costal margin
nd iliac crest, and hip circumferences over light clothing at
he level of the widest diameter around the buttocks.
eight, height, and waist and hip measures were missing in
.28%, 1.35%, and 3.5% of subjects, respectively. Hyper-
ension was assessed using information on self-reported
istory and/or use of antihypertensive medication (10).
ABORATORY MEASURES. Blood samples were available in
1,508 (79%) of 27,098 cases and controls. Nonfasting
lood samples (20 ml) were drawn from every subject and
entrifuged within 2 h of admission, separated into 6 equal
olumes, and frozen immediately at 20°C or 70°C after
rocessing. Centers were instructed to draw blood from
ases within 24 h of symptom onset, although 21% of these
amples were obtained after 24 h because of delays in patient
resentation. Samples were shipped in nitrogen vapor tanks by
ourier from every site to a blood storage site, where they were
tored at160°C in liquid nitrogen (Hamilton, Ontario) or at
70°C (India and China). Blood samples from all countries 5ther than China were analyzed in
amilton for total cholesterol,
igh-density lipoprotein (HDL)
holesterol, ApoB, ApoA1, and
bA1c. HDL is an established
isk factor for coronary artery
isease, and recent reports have
uggested that ApoB and ApoA1
re superior to traditional lipid
easures for coronary heart dis-
ase risk prediction (11,12). The
bA1c measures were used to
elp identify nondiabetic patients
ith probable hyperglycemia and
re a strong indicator of type 2
iabetes (receiver-operating char-
cteristic area under the curve 
.86) (13). As there is currently no
niversal demarcation point to define high HbA1c values, we
sed a cutoff point of 6.5% which corresponds to the 90th
ercentile in nondiabetic subjects and median value among
ubjects with diabetes.
The methods for analyses have been reported previously
9) and are summarized in Online Appendix 2. A total of
6,903 subjects, 12,297 cases and 14,606 controls, was
vailable for this analysis, and among these subjects, 6,905
ases and 9,109 controls had both HbA1c and HDL
holesterol measurements. The INTERHEART study was
pproved by appropriate regulatory and ethics committees in
ll participating countries and centers (9).
S DEFINITIONS. The MS was evaluated using 2 defini-
ions, as summarized in Table 1. Both definitions were
ased on the same component risk factors: 1) self-reported
iabetes mellitus or HbA1c 6.5%; 2) self-reported hyper-
ension or use of a prescribed antihypertensive medication;
) abdominal obesity as measured by the ratio of the waist
nd hip circumference (World Health Organization
WHO]) and waist circumference (International Diabetes
ederation [IDF]); and 4) abnormal lipid concentrations
etermined from serum HDL cholesterol measures. The
HO definition consisted of diabetes/hyperglycemia com-
ined with any 2 other component factors, whereas the IDF
efinition was composed of abdominal obesity using ethnic-
pecific cutoffs plus any 2 other factors (Table 1).
tatistical analyses. Simple associations were assessed us-
ng frequency tables and Pearson’s chi-square tests for 2
ndependent proportions. Prevalence rates across distinct
ubgroups (e.g., by region, country, ethnicity) were adjusted
or age using the direct standardization approach (14).
The findings presented are for models fit with uncondi-
ional logistic regression, adjusted for the matching criteria
age and sex), geographic region, and potential confounders.
nmatched analyses were used because perfect matching
as not possible for 14% (1,763 of 12,461) of MI cases and
Abbreviations
and Acronyms
Apo  apolipoprotein
CI  confidence interval
Hb  hemoglobin
HDL  high-density
lipoprotein
IDF  International
Diabetes Federation
MI  myocardial infarction
MS  metabolic syndrome
OR  odds ratio
PAR  population
attributable risk
WHO  World Health
Organization% (738 of 14,637) of controls. Performing a strict matched
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Metabolic Syndrome and MI Risk May 25, 2010:2390–8nalysis would lead to a significant loss of information,
ecause missing data on a risk factor in a case or control
ould result in the exclusion of the case-control pair from
ll analyses. Therefore, we widened the age-matching cri-
eria, as well as employed frequency matching of cases and
ontrols, utilizing age and sex strata. In addition, the
arameter estimates among the many different methods
conditional logistic regression, mixed models, and uncon-
itional logistic regression) were within 5% of each other,
ith a slight attenuation of effect estimates in the uncon-
itional models compared with the conditional models.
ence, findings presented may be interpreted as providing a
light underestimation of effect sizes for most comparisons.
Statistical analyses and graphics were produced using the
AS system version 9.1 (SAS, Cary, North Carolina). All
tatistical tests of hypotheses are 2-sided. Population attrib-
table risks (PARs) and 95% confidence intervals (CIs) were
alculated for various risk factors in the study, adjusting for
onfounders in a similar fashion to the corresponding
ogistic regression models for odds ratio (OR) estimates. All
Rs of MS on MI are adjusted for by age, sex, smoking,
nd region where indicated. The effect on MI by MS was
ompared with the effect of its component risk factors
onsidered singly and in combination. The effect on MI
hen 2, 3, and all 4 MS factors occur was assessed to help
dentify individual factors that strengthened or weakened
ssociations between MS and MI. For these analyses of
ombined risk factors, the component factors were defined
sing the previously defined INTERHEART study cutoff
oints for abdominal obesity (upper tertile of waist-to-hip
atio:0.90 in men and0.83 in women) (15) and elevated
poB/ApoA1 ratio (1 SD above the sex-specific log-
ransformed mean value in control subjects: 1.054 in men
nd 0.957 in women after retransformation back to the
riginal scale) (11). Lastly, the MI risk conferred by risk
actors with values above and slightly below the pre-defined
hreshold was evaluated, with “normal” values as the refer-
Definitions of Metabolic Syndrome Used in This StudyTable 1 2 Definitions of Metabolic Syndrome Used in This Stud
Criteria WHO Definition
1. Diabetes mellitus History of diabetes or HbA1c 6.5%
2. Hypertension History of treated/untreated hypertension
3. Abdominal obesity Males WHR 0.90; females WHR 0.85
4. Abnormal lipid profile Males HDL-C 0.90 mmol/l or taking fibrate/niacin
Females HDL-C 1.03 mmol/l or taking fibrate/
Total
Metabolic syndrome Diabetes mellitus  2 or 3 other factors
bA1c  glycated hemoglobin; HDL-C  high-density lipoprotein cholesterol; IDF  International D
atio.nce group. The effect on MI when 3 or more subthreshold misk factors were present was assessed. The range of values
sed to define subthreshold risk are presented in Online
ppendix 3. Likelihood ratio tests were used to compare
R values for component risk factors across study groups
e.g., age, sex, ethnicity, and region) and to test for inter-
ctions of these risk factors considered in combination. The
djusted ORs were presented as forest plots, with corre-
ponding PAR values indicated.
esults
S factors. The proportion of MS component factors
aries significantly between MI cases and controls (Table 2).
or both definitions of MS, the majority of cases and
ontrols have at least 1 MS-related factor, but cases are
ore likely to have 3 MS-related factors (p  0.0001).
sing the WHO definition of MS, the presence of each
omponent factor (diabetes, hypertension, abdominal obe-
ity, and low HDL cholesterol) is more common in cases
ompared with controls (p  0.0001 for each factor).
imilar differences are observed for the IDF-defined risk
actors. Subjects who had MS were older (59.5 years vs. 56.9
ears, p 0.0001), less likely to be smokers (28.4% vs. 36.0%,
 0.0001), less likely to exercise (11.3% vs. 17.8%, p 
.0001), and proportionately more were women (32.5 vs. 22.7,
 0.0001), compared with subjects who did not have MS.
Using the WHO definition of MS, the age- and obesity-
djusted prevalence of MS among MI cases is 22.1% (95%
I: 21.1% to 23.1%), and among controls it is 10.1% (95%
I: 9.5% to 10.7%; p  0.0001). Using the IDF definition,
he age- and obesity-adjusted prevalence of MS among MI
ases is 28.1% (95% CI: 27.0% to 29.2%), and among
ontrols it is 17.2% (95% CI: 16.4% to 18.0%; p  0.0001).
sing either definition, the unadjusted (and age- and
besity-adjusted) prevalence of MS among MI cases was
ignificantly higher among women (32.1%, 95% CI: 29.9%
o 34.4% [29.5%, 95% CI: 27.3% to 31.7%]) compared with
IDF Definition
History of diabetes or HbA1c 6.5%
History of treated/untreated hypertension
Europeans, sub-Saharan Africans, and Eastern Mediterranean and Arabs:
Males WC 94 cm;
Females WC 80 cm
South Asians, Chinese, and South and Central Americans:
Males WC 90 cm;
Females WC 80 cm
Japanese:
Males WC 90 cm;
Females WC 80 cm
Males HDL-C 1.03 mmol/l or taking fibrate/niacin;
Females HDL-C 1.29 mmol/l or taking fibrate/niacin
Abdominal obesity  2 or 3 other factors
s Federation; WC  waist circumference; WHO World Health Organization; WHR  waist to hipy
;
niacinen (19.5%, 95% CI: 18.4% to 20.6% [19.6%, 95% CI:
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May 25, 2010:2390–8 Metabolic Syndrome and MI Risk8.5% to 20.7%]). The age- and obesity-adjusted prevalence
f MS in MI cases was significantly higher in South Asians
29.8%, 95% CI: 27.1% to 32.5%), other Asians (28.7%,
5% CI: 24.6% to 32.8%), Arabs (25.4%, 95% CI: 22.7% to
8.1%), Black Africans (33.6%, 95% CI: 24.0% to 47.6%),
nd Colored Africans (24.6%, 95% CI: 18.9% to 30.3%)
ompared with Europeans (14.7%, 95% CI: 12.8% to
6.6%), Chinese (20.9%, 95% CI: 19.1% to 22.7%), and
atin Americans (18.9%, 95% CI: 16.0% to 21.8%).
S and component risk factors. The MS defined by
HO is a risk state for MI (OR: 2.69, 95% CI: 2.45 to
.95) and the PAR of MSWHO associated with MI is 14.5%
95% CI: 12.7% to 16.3%) (Fig. 1A). Using the IDF
efinition, MS is also a significant risk state for MI (OR:
.20, 95% CI: 2.03 to 2.38), and the PAR of MS associated
ith MI is 16.8% (95% CI: 14.8% to 18.8%) (Fig. 1B).
As shown in Figure 1A, the risk of MI conferred by MS
s significantly higher than that of low HDL cholesterol
p  0.0001) or abdominal obesity (p  0.0001) evaluated
ingly, but virtually the same as the risk conferred by
iabetes or hypertension alone. A similar pattern of results
s observed when using WHO or IDF criteria to define MS
Fig. 1B).
Figure 2 shows the association of MI with different
ombinations of risk factors. The presence of additional risk
actors is associated with an incremental increase in risk of
I. Diabetes combined with hypertension (OR: 3.59, 95%
I: 3.25 to 3.97) is associated with a risk of MI comparable
o having all 4 MS risk factors (OR: 3.76, 95% CI: 3.00 to
.72). Abdominal obesity and high ApoB/ApoA1 ratio
ointly are associated with a significantly lower risk of MI
OR: 2.12, 95% CI: 1.96 to 2.29) compared with having
iabetes or hypertension, although considering people in the
op and bottom quintiles of ApoB/ApoA1 ratio (men:
1.06 and 0.62; women: 0.98 and 0.56) plus abdom-
nal obesity confers a higher risk of MI (OR: 2.77, 95% CI:
.52 to 3.06).
Figure 3A presents the association of MI with risk factor
revalence of Metabolic Syndrome Components in Controls and CaTable 2 Prevalence of Metabolic Syndrome Components in Con
Metabolic Syndrome
Factors
Overall
Controls Cases p Value C
WHO and IDF definitions
Diabetes or HbA1c 6.5% 1,843 (19.6) 3,045 (39.7) 0.0001 5
Hypertension 3,058 (23.4) 5,384 (43.9) 0.0001 9
WHO definition
Abdominal obesity 8,318 (63.7) 7,973 (73.0) 0.0001 1,8
Low HDL-C 4,953 (40.9) 4,470 (46.9) 0.0001 1,1
Metabolic syndrome 908 (10.0) 1,555 (22.5) 0.0001 2
IDF definition
Abdominal obesity 6,191 (47.4) 5,744 (52.6) 0.0001 2,0
Low HDL-C 7,250 (59.9) 6,251 (65.5) 0.0001 1,8
Metabolic syndrome 1,526 (16.8) 2,008 (29.1) 0.0001 6
bbreviations as in Table 1.omponents as defined using cutoff values at or just below phe thresholds indicated in Table 1. The clustering of 3
ubthreshold risk factors is associated with a significantly
reater risk of MI (OR: 1.50, 95% CI: 1.24 to 1.81; p 
.001) compared with having component factors with “nor-
al” values, but lower than the risk conferred by an
ggregation of risk factors with values above the threshold
oints (OR: 2.73, 95% CI: 2.49 to 3.00; p  0.001). For
iabetes and abdominal obesity, the MI risk increased
ncrementally with higher values (p 0.001). Similar results
re observed when using the WHO and IDF criteria to
efine MS (Fig. 3B). The PAR of MS associated with MI
s 5% for most risk factors just below the threshold cutoff
oints and for the clustering of these factors (PAR  1.3,
5% CI: 0.6 to 2.1) (Figs. 3A and B).
ge and sex variation in MS and MI. As shown in
igure 4A, using the WHO definition, the OR of MS is
ignificantly higher in women compared with men (OR:
.53, 95% CI: 2.97 to 4.18 vs. OR: 2.37, 95% CI: 2.13 to
.65; p 0.05). By age groups, the association between MS
nd MI is stronger among younger compared with older
ubjects (OR: 3.23, 95% CI: 2.80 to 3.72 vs. OR: 2.35, 95%
I: 2.08 to 2.66, p  0.05) (Fig. 4A). Likelihood ratio tests
how significant heterogeneity by sex (p  0.0001) and age
p  0.002). The OR is significantly greater in younger
omen than in younger men (OR: 4.61, 95% CI: 3.61 to
.90 vs. OR: 2.66, 95% CI: 2.24 to 3.16, p 0.001), but not
n older women compared with older men (OR: 2.81, 95%
I: 2.21 to 3.59 vs. OR: 2.19, 95% CI: 1.90 to 2.53) (Fig.
A). Similar results are observed when using the IDF
efinition to classify MS (Fig. 4B).
egional and ethnic variation in MS and MI. The
ssociation of MS to MI across geographic regions and
thnic groups is shown in Online Appendixes 4 and 5,
espectively. The associations of MS to MI are directionally
imilar across all groups. Using the WHO definition, a
ignificantly stronger MS-MI association occurs among
eople living in Southeast Asia, specifically Thailand, Phili-
Overall and by Sexand Cases, Overall and by Sex
Women Men
ls Cases p Value Controls Cases p Value
3.6) 973 (51.1) 0.0001 1,305 (18.3) 2,072 (36.0) 0.0001
1.1) 1,729 (58.8) 0.0001 2,081 (20.9) 3,655 (39.2) 0.0001
8.5) 1,825 (70.4) 0.0001 6,481 (65.3) 6,148 (73.8) 0.0001
9.4) 1,144 (49.9) 0.0001 3,796 (41.4) 3,326 (45.9) 0.0001
2.1) 533 (32.1) 0.0001 641 (9.3) 1,022 (19.5) 0.0001
6.2) 1,848 (71.3) 0.0001 4,113 (41.2) 3,896 (46.8) 0.0001
4.3) 1,696 (73.9) 0.0001 5,361 (58.5) 4,555 (62.8) 0.0001
7.3) 812 (49.0) 0.0001 921 (13.4) 1,196 (22.8) 0.0001ses,trols
ontro
38 (2
77 (3
37 (5
57 (3
67 (1
78 (6
89 (6
05 (2pines, Singapore, and Japan (OR: 4.51, 95% CI: 3.34 to
6
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Metabolic Syndrome and MI Risk May 25, 2010:2390–8.08) (Online Appendix 4A), and among subjects classified
s “other Asian,” comprising people of Thai, Filipino, and
apanese origin (OR: 5.10, 95% CI: 3.61 to 7.19) (Online
ppendix 5A), compared with most other regional or ethnic
ubgroups. The associations for several regions including
outh Asia, the Middle East, Africa, and China are
ot significantly different from those of other regions.
verall, similar findings are observed when using the IDF
riteria (Online Appendixes 4B and 5B).
iscussion
he INTERHEART study is the first large-scale, multi-
Figure 1 Odds Ratio and PAR of MI Associated
With MS Using WHO and IDF Definitions
Odds ratio (adjusted for age, sex, region, and smoking status) and population
attributable risk (PAR) of myocardial infarction (MI) associated with metabolic
syndrome (MS) using the (A) World Health Organization (WHO) definitions and
the (B) International Diabetes Federation (IDF) definitions, by MS component
factors. See Table 1 for criterion definitions. CI  confidence interval; HDL 
high-density lipoprotein.thnic, international investigation showing that the MS is a tignificant risk factor for acute MI. The presence of diabetes
r HbA1c 6.5% combined with 2 or more MS related
actors is predictive of MI among men and women, young
nd old, across all geographic regions and ethnic groups.
dditionally, the presence of MS confers a similar risk of
I compared with diabetes or hypertension alone, yet
tronger effects than other component factors including
bdominal obesity and low HDL cholesterol. Furthermore,
Figure 2 Odds Ratio and PAR of MI
Associated With MS, by INTERHEART Data
Odds ratio (adjusted for age, sex, region, and smoking status) and PAR of MI
associated with MS defined from INTERHEART study data, by MS component
factors in combination. The component factors were defined using the previ-
ously defined INTERHEART study cutoff points for abdominal obesity (upper ter-
tile of waist-to-hip ratio: 0.90 in men and 0.83 in women) (15) and
elevated apolipoprotein (Apo) B/ApoA1 ratio (1 SD above the sex-specific log-
transformed mean value in control subjects: 1.054 in men and 0.957 in
women, after retransformation back to the original scale) (11). Additional analy-
ses assessed the top versus bottom quintiles of ApoB/ApoA1 ratio (men:
1.060 and 0.620; women: 0.978 and 0.563). Abd Obes  high waist-
to-hip ratio; DM  diabetes mellitus; HTN  hypertension; lipids  elevated
ApoB/ApoA1 ratio (based on 1 SD above the log-transformed mean value in
controls); lipid upper quintile  elevated ApoB/ApoA1 ratio (based on top vs.
bottom quintiles of ApoB/ApoA1 ratio); other abbreviations as in Figure 1.he PAR of MS on MI is substantially lower than the PAR
o
i
a
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May 25, 2010:2390–8 Metabolic Syndrome and MI Riskf several component factors considered separately depend-
ng on the definition used, suggesting that MS accounts for
smaller number of MI cases in a population compared
Figure 3 Odds Ratio and PAR of MI
Associated With MS, by MS Component Factors
Odds ratio (adjusted for age, sex, region, and smoking status) and PAR of MI
associated with MS using the (A) WHO definitions and the (B) IDF definitions,
by MS component factors, both at and just below the threshold cutoff values.
The range of values used to define subthreshold risk of MI for each MS risk
factor is shown in Online Appendix 3. ‡MI risk conferred by the presence of
3 subthreshold risk factors compared with having 3 subthreshold risk fac-
tors or “normal” values. ¶MI risk conferred by the presence of 3 superthresh-
old risk factors compared with having 3 superthreshold risk factors or
“normal” values. Abbreviations as in Figure 1.ith several of its constituent components. Our findings cuggest that the risk associated with MS is not greater than
he sum of its component factors.
The MS refers to a cluster of risk factors which when
resent together is believed to confer an increased risk of
ardiovascular disease (1,2). Subjects with MS have a higher
Figure 4 Odds Ratio and PAR of MI
Associated With MS, by Age and Sex
Odds ratio (adjusted for age, sex, region, and smoking status) and PAR of MI
associated with MS using the (A) WHO definitions and the (B) IDF definitions,
by age and sex subgroups. The demarcation point for classifying young sub-
jects was age 65 years for women and age 55 years for men (9). Abbrevia-
tions as in Figure 1.ardiovascular disease risk than do subjects without the
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Metabolic Syndrome and MI Risk May 25, 2010:2390–8yndrome (3–5). Using the INTERHEART study data, we
ave demonstrated that using either the WHO or IDF
efinition, the presence of MS is associated with 2.5-fold
ncrease in the risk of acute MI. Cabre et al. (16) recently
eported similar findings for cardiovascular disease using
hese definitions. However, the risk of MI when 3 MS
actors are present does not appear to be greater than the
isk conferred by some of its component parts, namely,
iabetes and hypertension. Others have also reported that
ndividual component factors and MS are associated with a
imilar degree of coronary heart disease risk (17,18). Thus,
hile it may be clinically feasible to make a diagnosis of
metabolic syndrome,” the MS classification appears to
erve only as a simple description of multiple risk factors for
ardiovascular disease that are commonly identified to-
ether, and not a syndrome associated with a cardiovascular
isk that is greater than the sum of its parts.
MS has been fraught with definitional problems, includ-
ng variation in the component factors used and differences
n risk factor thresholds (7,8). In our analysis, the use of 2
ifferent syndrome definitions (WHO and IDF) yielded a
imilar pattern of results relating MI to MS and its
omponent factors, which is consistent with the premise
hat different definitions of MS have similar predictability in
elation to coronary risk (19). There is also considerable
vidence of a dose-response relationship between MI and
isk factor measures including MS component factors (20).
owever, to our knowledge, previous studies have yet to
eport an incremental increase in MI risk as risk factors less
han threshold values cluster together (21–23). In our
nalysis, an aggregation of risk factors with values below
heir threshold was associated with a significantly greater
isk of MI, compared with having component factors with
ormal values, but lower than the risk conferred by an
ggregation of risk factors with values above the threshold
oints. These findings of a dose-response relationship
etween risk factor severity and MI risk suggest that a
tandard definition of MS loses information when contin-
ous variables are converted to categorical variables and
rovide support for calls to replace the categorical definition
f MS with a scoring system (24) that may involve each risk
actor being assigned a weight based on its level and a
egression formula developed to estimate risk.
The finding that MI risk increases as more component
actors are present is consistent with previous observations
howing the presence of more risk factors is associated with
n incremental increase in subclinical atherosclerosis and
25) incident coronary heart disease (19,26,27). There is
ubstantial evidence showing that diabetes combined with
ypertension confers a particularly dangerous MI risk (28),
hich is in keeping with our observation that the joint effect
f diabetes and hypertension on MI is similar to that of
aving all 4 MS component factors. Both conditions are
ommon and frequently coexist (29), as 40% to 60% of
ubjects with type 2 diabetes have hypertension (30). More-
ver, a substantial proportion of people with diabetes and sypertension have abdominal obesity (31), which we also
bserved (77%). In addition, our finding that MI risk
ncreases incrementally as more component factors are
resent suggests that a dichotomous definition of MS based
n 3 risk factors is too simplistic and may fail to identify
igh-risk subjects who have only 1 or 2 risk factors.
oreover, this definition of MS leads to a substantially
ower prevalence of MS than its component factors. This
artly explains our observation that the PAR of MS is lower
han the PAR of several component factors, and indicates
hat MS accounts for a smaller number of MI cases in a
opulation compared with several of its constituent compo-
ents. This finding highlights an important limitation
ssociated with MS diagnosis.
Our finding that the syndrome conveys information that
s no greater than an assessment of diabetes comprised by
elf-report and blood HbA1c measures may have important
linical implications. Most subjects with diabetes have MS,
s prevalence estimates in the U.S. are in the range of 60%
o 70% (32), and HbA1c (33) and blood glucose (34) are
ndependent predictors of intimal-medial thickness. In
iddle-aged Austrian women, blood glucose was the stron-
est MS-component related to intimal-medial thickness
34). Biochemical markers of glucose homeostasis are usu-
lly routinely available in a clinical setting, and question-
aires to assess cardiovascular risk factors including diabetes
ay be administered readily. Screening patients for diabetes
ay provide a more practical and cost efficient approach to
ssessing MI risk compared with a more involved examina-
ion to diagnose MS.
The INTERHEART study is the first large study which
learly shows that the association between the MS and MI
s qualitatively similar (although some quantitative differ-
nces exist) across sex, region, and ethnic groups. The PAR
f MS on MI, which is a function of the OR and the
revalence of the MS in the controls, is higher among
omen and among Southeast Asians, and is significantly
ower among the Chinese compared with most other ethnic
ubgroups. These findings are concordant with previous
bservations showing higher prevalence rates of MS com-
onent factors in Southeast Asians (9,35). The PAR values
or other groups including South Asians, Arabs, and Afri-
ans were not significantly different from other groups,
espite previous evidence that these groups have higher
ates of diabetes or low HDL cholesterol (9,35,36), and
ore abdominal obesity (9,37). Unlike previous studies,
owever, the aim of our study was to evaluate the PAR of
S on MI within ethnic subgroups, rather than making
etween-group comparisons. Lastly, the risk of MI is not
ignificantly associated with MS among North Americans, a
nding that has been reported previously (38,39). However,
ur subanalyses by ethnicity show that MS is consistently
ssociated with MI, which suggests that the null association
n North America likely reflects the heterogeneity of the
ubjects recruited from Canada and the U.S.
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ith MS, have a significantly higher risk of MI and PAR
alues compared with younger and older men. This finding
s consistent with that of previous studies showing that
oung women with risk factors have an increased relative
isk of MI compared with men (albeit a lower absolute risk
f having coronary heart disease) (9,40), and supports the
remise that risk factors such as diabetes or hypertension
hould be treated aggressively in younger women when they
re detected (41). Whether our finding represents a real
ifference in the propensity to develop MI when MS is
resent between women and men or reflects selection
ifferences in cases and controls is unclear.
tudy limitations. Some limitations, including selection of
nd ascertainment of risk factors among cases and controls
n the INTERHEART study, have been previously re-
orted in detail (9). In addition, in this analysis we may have
nderestimated the prevalence of MS, its strength of asso-
iation with MI, and its PAR, since we relied on self-
eported measures of diabetes (without conducting formal
ral glucose tolerance tests or fasting glucose assessment)
nd hypertension (we obtained blood pressure measures in
oth cases and controls, but the values could be systemati-
ally affected by the acute MI and treatment in cases).
owever, we supplemented the diabetes information with
easurements of blood HbA1c to help identify nondiabetic
ubjects with probable hyperglycemia (13), and data on
sage of antihypertensive medication to improve the accu-
acy of reported risk factors components (10). Moreover,
ur analysis showed that the prevalence of MS in North
merican controls (15%) was comparable to the prevalence
eported previously in adults residing in the U.S. (22%)
42). When we repeated the analyses using IDF criteria, the
esults were similar to those of the WHO definition of MS,
hich provides further assurance as to the reliability of our
ndings. The use of frequency matching of cases and
ontrols was not optimal. However, our approach produced
irtually the same results or a slight attenuation of the effect
stimates compared with conditional logistic regression and
ixed models, which suggests that our findings likely
rovide a slight underestimation of the effect sizes. Because
ata on blood triglycerides are not available and case
ubjects and most control subjects were not fasting, tri-
lycerides are not included in the definitions of MS.
owever, we have incorporated HDL criteria into our
efinitions of MS. Furthermore, associations between
riglycerides and MI are reported to be weaker than the
ffects of hypertension or diabetes (43), and thus, their
bsence is unlikely to alter the key findings. Lastly, other
efinitions of MS exist that also include novel variables,
uch as prothrombotic or proinflammatory indices, which
ere not evaluated in this study. The strengths of our
nalysis included our use of a standardized protocol
mong large numbers of people including substantial
umbers of women and men from multiple ethnic groups
ampled across a wide age range.onclusions
S is a risk state for acute MI in women and men, from all
egions and ethnic groups worldwide. The risk of MI
ssociated with MS does not appear to be greater than the
isk conferred by its component factors. The use of dichot-
mous risk factors may underestimate risk among persons
ith subthreshold values and further limit the usefulness of
S classification to predict MI risk.
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APPENDIX
or an expanded discussion of the INTERHEART study,
lease see the online version of this article.
